Raymond James Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $9

Benzinga · 08/30 12:46
Raymond James analyst Ryan Deschner initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Outperform rating and announces Price Target of $9.